Icu Medical, Inc. shares rise 4.80% intraday after SeaStar Medical's investor presentation on transforming treatments for critically ill patients.

Icu Medical, Inc. rose 4.80% in intraday trading, with SeaStar Medical, a company with a patented, proprietary SCD platform, presenting an investor presentation. The presentation highlighted the company's best-in-class technology, which is clinically proven to reduce mortality and has shown a dramatic reduction in economic burden. The company has FDA approval for pediatric acute kidney injury with sepsis in 2024 and is continuing to expand into additional children's hospitals. The company is also making progress in its pivotal trial, having achieved 125 of 200 patients enrolled in the NEUTRALIZE-AKI pivotal trial, with an interim analysis of the first 100 patients anticipated in 3Q'25.